Doxorubicin: The good, the bad and the ugly effect
Abstract
The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients' life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Doxorubicin produces multiple severe side effects including cumulative cardiotoxicity, acute nausea and vomiting, gastrointestinal disturbances, alopecia baldness, and neurologic disturbances.
“The latter produces multiple severe side effects including the cumulative cardiotoxicity, acute nausea and vomiting, gastrointestinal disturbances, alopecia baldness, and neurologic disturbances (Carvalho et al., 2009).”
From An Arthropod Hormone, Ecdysterone, Inhibits the Growth of Breast Cancer Cells via Different Mechanisms (2020) · cites this paper as Carvalho et al., 2009
Cited by
Sorted by citations
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,469 · see citing works
“Other side effects of extravasation include cellulitis, thrombophlebitis and joint movement limitation as a result of painful induration (pathological hardening of tissue).([7])”
BackgroundInfluentialThorn, C. F., Oshiro, C. M., Marsh, S., Hernandez‐Boussard, T., McLeod, H. L., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,661 · see citing works
“A B C B 1 rs 35 65 79 60 L eu 66 2A rg G In cr ea se d re si st an ce 17 35 25 37 b [4 6]”
BackgroundInfluentialDNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,125 · see citing works
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska‐Kołat, Ż., Çeli̇k, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 864 · see citing works
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G. N., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 593 · see citing works
“…explanations for doxorubicin toxicity include inhibition of nucleic acid and protein synthesis, release of vasoactive amines, alterations in adrenergic function and adenylate cyclase activity, changes in calcium transport, and alterations in cellular iron metabolism (Carvalho et al., 2009).”
BackgroundDoxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2013) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 568 · see citing works
“Biochem Biophys Res Commun 2009;378(3):450–455.”
BackgroundInfluentialSelf-citationOxidative stress injury in doxorubicin-induced cardiotoxicity
Mei, S., Hong, L., Xinyong, C., Bin, X., Ping, Z., & Shao, L. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.02.013 · Cited by 571 · see citing works
Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery
Li, Y., Maciel, D., Rodrigues, J., Shi, X., & Tomás, H. (2015) · Chemical Reviews · doi:10.1021/cr500131f · Cited by 480 · see citing works
Zhang, X., Hu, C., Kong, C., Song, P., Wu, H., Xu, S., Yuan, Y., Deng, W., Ma, Z., & Tang, Q. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0372-z · Cited by 446 · see citing works
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442 · see citing works
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S. R., Noubissi, F. K., Ray, P. C., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 401 · see citing works
Curcumin, the golden spice in treating cardiovascular diseases
Li, H., Sureda, A., Devkota, H. P., Pittalà, V., Barreca, D., Sanches-Silva, A. T., Tewari, D., Xu, S., & Nabavi, S. M. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.01.010 · Cited by 339 · see citing works
Single walled carbon nanotubes as drug delivery vehicles: Targeting doxorubicin to tumors
Meng, L., Zhang, X., Lu, Q., Fei, Z., & Dyson, P. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.004 · Cited by 336 · see citing works
“Take, for example, the anthracycline, doxorubicin (DOX), a drug widely used in chemotherapy due to its efficacy in fighting a wide range of cancers [2], with particularly important applications in the treatment of breast cancer.”
BackgroundMitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 312 · see citing works
“The anthracyclines, for example, were originally envisioned as DNA-interacting agents, but research subsequently uncovered multiple cellular targets and effects including the ability to create iron-mediated free oxygen radicals that damage cellular components including membranes, intercalate between base pairs interfe…”
BackgroundIncreasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Meredith, A., & Dass, C. (2016) · The Journal of pharmacy and pharmacology · doi:10.1111/jphp.12539 · Cited by 283 · see citing works
“It is often used to treat acute leukaemia,([3]) breast cancer([4]) and childhood solid tumours,([5]) non-Hodgkin lymphomas,([6]) Hodgkin’s disease([7]) and soft tissue sarcomas.([8]) Unfortunately, despite being highly effective, doxorubicin is also nonselective to cancer cells, so its use is significantly limited due…”
BackgroundThe design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy
Han, H., Wang, H.-M., Jangili, P., Li, M., Wu, L., Zang, Y., Sedgwick, A. C., Li, J. X., He, X., James, T. D., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00673a · Cited by 304 · see citing works
Hu, C., Zhang, X., Wei, W., Zhang, N., Wu, H., Ma, Z., Li, L., Deng, W., & Tang, Q. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.003 · Cited by 261 · see citing works
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
Gabizón, A., Patil, Y. P., & La-Beck, N. M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.10.003 · Cited by 251 · see citing works
“Doxorubicin, also known as adriamycin, is the most widely used nthracycline, and has demonstrated significant therapeutic activty in many cancer types, being regarded as one of the most potent hemotherapeutic drug approved (Carvalho et al., 2009).”
BackgroundAdvances in Delivery Systems for Doxorubicin
Zhao, N., Woodle, M. C., & Mixson, A. J. (2018) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000519 · Cited by 245 · see citing works
“Efforts to mitigate Dox cardiomyopathy and other adverse effects have been undertaken via liposomal drug delivery [6,7].”
BackgroundEnzymatic methods for glyco(diversification/randomization) of drugs and small molecules
Gantt, R. W., Peltier, P., & Thorson, J. S. (2011) · Natural Product Reports · doi:10.1039/c1np00045d · Cited by 245 · see citing works
Hemdan, M., Ali, M. A., Doghish, A. S., Mageed, S. S. A., Elazab, I. M., Khalil, M. M., Mabrouk, M., Das, D. B., & Amin, A. S. (2024) · Sensors · doi:10.3390/s24165143 · Cited by 247 · see citing works
“Therefore, optimising the dose administered to cancer patients and monitoring it is vital in doxorubicin therapy [173].”
BackgroundAgudelo, D., Bourassa, P., Bérubé, G., et al. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.02.028 · Cited by 229 · see citing works
Pooja, D., Panyaram, S., Kulhari, H., et al. (2014) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2014.03.041 · Cited by 224 · see citing works
Agudelo, D., Bourassa, P., Bruneau, J., Bérubé, G., Asselin, É., & Tajmir‐Riahi, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043814 · Cited by 214 · see citing works
“The injury to nontargeted tissues often complicates cancer treatment by limiting doxorubicin dosage and diminishing the quality of patients’ life during and after doxorubicin treatment [1].”
Nanoparticles with dextran/chitosan shell and BSA/chitosan core—Doxorubicin loading and delivery
Qi, J., Yao, P., He, F., Yu, C., & Huang, C. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.063 · Cited by 215 · see citing works
Du, K., Feng, J., Gao, X., et al. (2022) · Light Science & Applications · doi:10.1038/s41377-022-00871-z · Cited by 215 · see citing works
New Insights into the Mechanism of the DNA/Doxorubicin Interaction
Pérez-Arnáiz, C., Busto, N., Leal, J. M., et al. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp411429g · Cited by 210 · see citing works
Multi‐Functional Liposome: A Powerful Theranostic Nano‐Platform Enhancing Photodynamic Therapy
Cheng, X., Gao, J., Ding, Y., Lu, Y., Wei, Q., Cui, D., Fan, J., Li, X., Zhu, E., Lu, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202100876 · Cited by 207 · see citing works
Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review
Mohajeri, M., & Sahebkar, A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.005 · Cited by 195 · see citing works
Stimuli-responsive nano-assemblies for remotely controlled drug delivery
Li, F., Qin, Y., Lee, J., Liao, H., Wang, N., Davis, T. P., Qiao, R., & Ling, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.051 · Cited by 197 · see citing works
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
Molinaro, C., Martoriati, A., Pélinski, L., & Cailliau, K. (2020) · Cancers · doi:10.3390/cancers12102863 · Cited by 200 · see citing works
Li, D., Liu, X., Pi, W., Zhang, Y., Yu, L., Cheng, X., Sun, Z., & Jiang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.808480 · Cited by 194 · see citing works
“Doxorubicin (DOX), a highly effective antitumor anthracycline antibiotic derived from Streptomyces, is commonly used for the treatment of many types of malignancies, including solid tumors, breast cancer, soft tissue sarcomas, lymphomas, and leukemia (Carvalho et al., 2009).”
BackgroundMetal–Organic Framework Composites for Theragnostics and Drug Delivery Applications
Osterrieth, J. W. M., & Fairen‐Jiménez, D. (2020) · Biotechnology Journal · doi:10.1002/biot.202000005 · Cited by 191 · see citing works
Reduced Graphene Oxide-Supported Gold Nanostars for Improved SERS Sensing and Drug Delivery
Wang, Y., Polavarapu, L., & Liz‐Marzán, L. M. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am501382y · Cited by 188 · see citing works
Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery
Biernacki, K. A., Daśko, M., Ciupak, O., Kubiński, K., Rachoń, J., & Demkowicz, S. (2020) · Pharmaceuticals · doi:10.3390/ph13060111 · Cited by 192 · see citing works
“Obtained compounds were tested in comparison with doxorubicin—widely used anticancer agent in the treatment of breast, bladder carcinomas, lymphoma, and acute lymphocytic leukemia [61,62].”
BackgroundSelf-Assembling Nucleic Acid Nanostructures Functionalized with Aptamers
Krissanaprasit, A., Key, C. M., Pontula, S., & LaBean, T. H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01332 · Cited by 183 · see citing works
Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity
Abushouk, A. I., Ismail, A., Salem, A. M. A., Afifi, A. M., & Abdel‐Daim, M. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.033 · Cited by 182 · see citing works
Adhikari, C., Das, A., & Chakraborty, A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00043 · Cited by 179 · see citing works
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells
Nicoletto, R. E., & Ofner, C. M. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04400-y · Cited by 178 · see citing works
Cheung, K. G., Cole, L., Xiang, B., Chen, K., Ma, X., Myal, Y., Hatch, G. M., Tong, Q., & Dolinsky, V. W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.607960 · Cited by 175 · see citing works
“Doxorubicin (DOX)(4) is a chemotherapeutic agent used to treat a range of cancers (1).”
BackgroundShen, J., He, Q., Gao, Y., Shi, J., & Li, Y. (2011) · Nanoscale · doi:10.1039/c1nr10580a · Cited by 172 · see citing works
Li, S., Yuan, S., Zhao, Q., Wang, B., Wang, X., & Li, K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.055 · Cited by 171 · see citing works
Bisht, A., Avinash, D., Sahu, K. K., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01648-0 · Cited by 178 · see citing works
“Since its discovery in the 1970s from Streptomyces peucetius var. caesius , it has become a widely used medication for cancer treatments [6, 7].”
Patel, N., Joseph, C. K., Corcoran, G. B., & Ray, S. D. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.02.002 · Cited by 169 · see citing works
Espinoza, S. M., Patil, H. I., Martín‐Martínez, E. S., Pimentel, R. G. C., & Ige, P. P. (2019) · International Journal of Polymeric Materials · doi:10.1080/00914037.2018.1539990 · Cited by 164 · see citing works
Self-Assembled Peptide Drug Delivery Systems
Yang, J., An, H., & Wang, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00707 · Cited by 160 · see citing works
Polymeric Engineering of Nanoparticles for Highly Efficient Multifunctional Drug Delivery Systems
Fortuni, B., Inose, T., Ricci, M., Fujita, Y., Zundert, I. V., Masuhara, A., Fron, E., Mizuno, H., Latterini, L., Rocha, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39107-3 · Cited by 155 · see citing works
Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics
Škubník, J., Pavlíčková, V. S., Ruml, T., & Rimpelová, S. (2021) · Biology · doi:10.3390/biology10090849 · Cited by 170 · see citing works
“Next, doxorubicin intercalates into the DNA and binds proteins involved in DNA replication and transcription, which results in inhibition of DNA, RNA, and protein synthesis followed by cell death triggering [22].”
BackgroundYe, M., Wang, X., Tang, J., Guo, Z., Shen, Y., Tian, H., & Zhu, W. (2016) · Chemical Science · doi:10.1039/c6sc00970k · Cited by 155 · see citing works
Optimised Electroporation for Loading of Extracellular Vesicles with Doxorubicin
Lennaárd, A. J., Mamand, D. R., Wiklander, R. J., Andaloussi, S. E., & Wiklander, O. P. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010038 · Cited by 154 · see citing works
“Its cumulative dose is a critical parameter determining the cardiovascular effect, limiting both higher doses and prolonged treatments [22,23].”
BackgroundDNA topoisomerases as molecular targets for anticancer drugs
Buzun, K., Bielawska, A., Bielawski, K., & Gornowicz, A. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1821676 · Cited by 156 · see citing works
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances
Kizek, R., Adam, V., Hraběta, J., Eckschlager, T., Smutný, S., Burda, J. V., Frei, E., & Stiborová, M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.006 · Cited by 149 · see citing works
“It induces fewer side effects, as administration at a minimum cumulative dosage from 500 to 1500 mg/m2 did not cause congestive heart failure, while safe cumulative doses of conventional doxorubicin are 350–400 mg/m2 (Carvalho et al., 2009; Puri et al., 2009).”
Nucleic acid-based drug delivery strategies
Tan, X., Jia, F., Wang, P., & Zhang, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.040 · Cited by 147 · see citing works
When Place Matters: Shuttling of Enolase-1 Across Cellular Compartments
Didiášová, M., Schaefer, L., & Wygrecka, M. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00061 · Cited by 145 · see citing works
“Doxorubicin is used in the treatment of the breast cancer, however its clinical use is limited as it causes severe side effects like mitochondrial damage in cardiomyocytes and subsequent apoptosis of these cells (Carvalho et al., 2009).”
BackgroundWang, S., Chen, B., Ouyang, L., Wang, D., Tan, J., Qiao, Y., Ge, S., Ruan, J., Zhuang, A., Liu, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202004721 · Cited by 141 · see citing works
A Review on Drug Delivery System for Tumor Therapy
Liu, G., Yang, L., Chen, G., Xu, F., Yang, F., Yu, H., Li, L., Dong, X., Han, J., Cao, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.735446 · Cited by 143 · see citing works
“DOX DOX, also known as adriamycin, is an anthracycline antibiotic isolated from the Streptomyces peucetius spp possessing aglyconic and sugar moieties (Carvalho et al., 2009; Chen et al., 2018).”
BackgroundMosafer, J., Abnous, K., Tafaghodi, M., Mokhtarzadeh, A., & Ramezani, M. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.12.009 · Cited by 141 · see citing works
Fan, C., CHENG, Y.-H., Ting, C.-Y., Ho, Y.-J., Hsu, P., Liu, H.-L., & Yeh, C. (2016) · Theranostics · doi:10.7150/thno.15297 · Cited by 140 · see citing works
“Although DOX has been shown to have anti-tumor properties in vivo (25), DOX is associated with several complications, such as cardiotoxicity, myelosuppression, and nephrotoxicity (26,27).”
BackgroundOdendahl, K., Solaß, W., Demtröder, C. R. D., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.06.001 · Cited by 139 · see citing works
Recent progress of aptamer‒drug conjugates in cancer therapy
He, J., Duan, Q., Ran, C., Fu, T., Liu, Y., & Tan, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.017 · Cited by 139 · see citing works
Wang, S., Wang, Y., Zhang, Z., Liu, Q., & Gu, J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.410 · Cited by 139 · see citing works
“its long-term application in chemotherapy, as it diminishes the quality of life of cancer patients.(3,4) For example, one case”
BackgroundSong, S., Chu, L., Liang, H., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01030 · Cited by 138 · see citing works
J. Kapadia, G., A. Azuine, M., Subba Rao, G., Arai, T., Iida, A., & Tokuda, H. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795347504 · Cited by 135 · see citing works
“Due to these side-effects and its red color, which causes urine, tears and sweat to turn pinkish red, doxorubicin (adriamycin) has earned the nicknames "red devil” and “red death” [19, 20].”
BackgroundZhang, Y., Xu, Y.-W., Qi, Y., Xu, L.-N., Song, S., Yin, L., Tao, X.-F., Zhen, Y.-H., Han, X., Ma, X.-D., et al. (2017) · Toxicology · doi:10.1016/j.tox.2017.01.007 · Cited by 136 · see citing works
“Many researches have also reported the increased inflammatory mediators together with inflammatory cell infiltration, indicating that inflammation plays a significant role in Dox-induced nephrotoxicity (Carvalho et al., 2009).”
BackgroundPei, P., Yang, F., Liu, J., et al. (2018) · Biomaterials Science · doi:10.1039/c8bm00005k · Cited by 136 · see citing works
Perche, F., Patel, N. R., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.003 · Cited by 136 · see citing works
Light‐ and pH‐Responsive Release of Doxorubicin from a Mesoporous Silica‐Based Nanocarrier
Knežević, N. Ž., Trewyn, B. G., & Lin, V. S. ‐. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201002960 · Cited by 132 · see citing works
Doxorubicin Delivery into Tumor Cells with Ultrasound and Microbubbles
Escoffre, J., Piron, J., Novell, A., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100397p · Cited by 131 · see citing works
Zhang, X., Zhu, J., Ma, Z., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.29907 · Cited by 130 · see citing works
“highly effective antitumor anthracycline antibiotic, which has been commonly used for the treatment of various cancers, including leukemias, lymphomas and solid tumors [1-3].”
BackgroundFong, M., Jin, S., Rane, M. J., Singh, R. K., Gupta, R. C., & Kakar, S. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042265 · Cited by 130 · see citing works
“Consistent with previous reports on Dox and WFA [4,5,12,17,18,30], we confirm that both agents produce ROS, although ROS was greater in WFA treated cells (Fig.”
BackgroundResultInfluentialLv, X., Yu, X., Wang, Y., Wang, F., Li, H., Wang, Y., Lu, D., Qi, R., & Wang, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047351 · Cited by 127 · see citing works
“Doxorubicin (DOX), as a broad-spectrum antitumor antibiotic, is frequently used in chemotherapy due to its excellent anticancer efficacy [1].”
BackgroundZhang, C., Liu, Z., Zheng, Y., Geng, Y., Han, C., Shi, Y., Sun, H., Zhang, C., Chen, Y., Zhang, L., et al. (2017) · Small · doi:10.1002/smll.201703306 · Cited by 126 · see citing works
Shaker, R. A., Abboud, S. H., Assad, H., et al. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0184-z · Cited by 126 · see citing works
Encapsulation of Antitumor Drug Doxorubicin and Its Analogue by Chitosan Nanoparticles
Sanyakamdhorn, S., Agudelo, D., & Tajmir‐Riahi, H. (2013) · Biomacromolecules · doi:10.1021/bm3018577 · Cited by 125 · see citing works
Agudelo, D., Bourassa, P., Bérubé, G., et al. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.02.032 · Cited by 124 · see citing works
Chen, Z.-A., Wu, C. ‐., Wu, S., Huang, C.-Y., Mou, C., Wei, K., Yen, Y., Chien, I.-T., Runa, S., Chen, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c08993 · Cited by 128 · see citing works
García‐Carbonero, R., Rinke, A., Valle, J. W., Fazio, N., Caplin, M. E., Gorbounova, V. A., O’Connor, J. M., Eriksson, B. K., Sørbye, H., Kulke, M. H., et al. (2017) · Neuroendocrinology · doi:10.1159/000473892 · Cited by 123 · see citing works
“Treatment should be discontinued in case significant cardiac function deterioration is documented [49,50].”
BackgroundDoxorubicin‐induced skeletal muscle atrophy: Elucidating the underlying molecular pathways
Hiensch, A. E., Bolam, K. A., Mijwel, S., Jeneson, J. A. L., Huitema, A. D. R., Kranenburg, O., van der Wall, E., Rundqvist, H., Wengström, Y., & May, A. M. (2019) · Acta Physiologica · doi:10.1111/apha.13400 · Cited by 126 · see citing works
“Studies were included when they met the pre‐specified inclusion criteria: (a) design: randomized controlled trials (RCT) or controlled trials (CT); (b) population: humans, aged 18 years and older, diagnosed with a solid tumour or (non‐) tumour‐bearing animals in vivo; (c) intervention: doxorubicin administration; (d)…”
MethodAfsar, T., Razak, S., Almajwal, A. M., & Aldisi, D. A. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.07.011 · Cited by 122 · see citing works
Kovacs‐Balint, Z., Werner, B., Rassi, A., Sass, J. O., Martin‐Fiori, E., & Bernasconi, M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.033 · Cited by 120 · see citing works
Effect of Coenzyme-Q10 on Doxorubicin-Induced Nephrotoxicity in Rats
El‐Sheikh, A. A. K., Morsy, M. A., Refaie, M. M. M., et al. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/981461 · Cited by 120 · see citing works
“Unfortunately, the use of Dox has been limited by the occurrence of dose-dependent toxicities to vital organs, as the heart, the kidney, and the liver [1].”
BackgroundDoxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
Peter, S., Alven, S., Maseko, R. B., et al. (2022) · Molecules · doi:10.3390/molecules27144478 · Cited by 117 · see citing works
“Urticaria, fever, cutaneous injuries, vomiting, necrosis, and ulceration are other toxic effects associated with doxorubicin, which can be fatal in some cases [2,13,24].”
BackgroundBiomedical applications of MnO2 nanomaterials as nanozyme-based theranostics
Sisakhtnezhad, S., Rahimi, M., & Mohammadi, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114833 · Cited by 122 · see citing works
Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
Belver, A. B., Giger-Pabst, U., Solaß, W., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2840-2 · Cited by 116 · see citing works
“Interestingly, doxorubicin has only moderate liver toxicity.(18) During PIPAC, only about 10 % of a usual systemic drug dose is applied into the abdomen.”
BackgroundVarela‐López, A., Battino, M. A., Navarro‐Hortal, M. D., Giampieri, F., Forbes-Hernández, T. Y., Romero‐Márquez, J. M., Collado, R., & Quiles, J. L. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110834 · Cited by 118 · see citing works
Tuning the In Vivo Transport of Anticancer Drugs Using Renal‐Clearable Gold Nanoparticles
Peng, C., Xu, J., Yu, M., Ning, X., Huang, Y., Du, B., Hernandez, E., Kapur, P., Hsieh, J., & Zheng, J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903256 · Cited by 112 · see citing works
Hughes, A. M., & Hu, N. (2023) · Cancers · doi:10.3390/cancers15164091 · Cited by 115 · see citing works
Ashrafizadeh, M., Hushmandi, K., Mirzaei, S., Bokaie, S., Bigham, A., Makvandi, P., Rabiee, N., Thakur, V. K., Kumar, A. P., Sharifi, E., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10325 · Cited by 108 · see citing works
“Antisuppressive activity of DOX has been successfully demonstrated in preclinical models and clinical trials on various cancers, including leukemia, lymphoma, sarcoma, and urogenital cancers, among others.(80,82) DOX mainly targets genetic components in nucleus and mitochondria inhibiting the cell growth and division.”
BackgroundChen, S., Zou, Y., Song, C., Cao, K., Cai, K., Wu, Y., Zhang, Z., Geng, D., Sun, W., Ouyang, N., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01018-w · Cited by 111 · see citing works
Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer
Sadreddini, S., Safaralizadeh, R., Baradaran, B., et al. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.11.013 · Cited by 107 · see citing works
Zhou, Z., Badkas, A., Stevenson, M., Lee, J., & Leung, Y. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.081 · Cited by 106 · see citing works
Ingato, D., Edson, J. A., Zakharian, M., & Kwon, Y. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b05377 · Cited by 105 · see citing works
Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model
Desai, V. G., Herman, E. H., Moland, C. L., Branham, W. S., Lewis, S. M., Davis, K. J., George, N. I., Lee, T., Kerr, S., & Fuscoe, J. C. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.10.025 · Cited by 105 · see citing works
Venkatesan, B., Prabhu, S. D., Venkatachalam, K., Mummidi, S., Valente, A. J., Clark, R. A., Delafontaine, P., & Chandrasekar, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.005 · Cited by 105 · see citing works
Gou, P., Liu, W., Mao, W., Tang, J., Shen, Y., & Sui, M. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00004k · Cited by 104 · see citing works
Wang, S., Song, P., & Zou, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.315812 · Cited by 104 · see citing works
“In clinical studies, doxorubicin has been proven to be a powerful and efficient genotoxic stress inducer to fight cancer, but at the same time, it leads to significant damage to normal tissues as well (56), especially in cardiomyocytes (57, 58).”
BackgroundKojima, K., McQueen, T. J., Chen, Y., Jacamo, R. O., Konopleva, M. Y., Shinojima, N., Shpall, E. J., Huang, X., & Andreeff, M. (2011) · Blood · doi:10.1182/blood-2011-02-334136 · Cited by 103 · see citing works
Hajra, S., Patra, A. R., Basu, A., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.088 · Cited by 102 · see citing works
miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway
Yin, Z., Zhao, Y., Li, H., et al. (2016) · Aging · doi:10.18632/aging.100876 · Cited by 101 · see citing works
“Besides its specific cardiotoxicity, doxorubicin also produces significant toxic side-effects in liver, brain and kidney [27].”
BackgroundWang, P., Wang, L., Lü, J., Hu, Y., Wang, Q., Li, Z., Cai, S., Liang, L., Guo, K., Xie, J., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.005 · Cited by 102 · see citing works
- Authors
- Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P.
- Affiliations
- Centro de Neurociências e Biologia Celular (PT)
- Corresponding author
- Moreira, Paula
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-09-01
- Volume
- 16
- Issue
- 25
- Pages
- 3267-3285
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2102897174
- Cited by
- 1,509
- References
- 0
- Citations by year
- 2026: 102 · 2025: 147 · 2024: 174 · 2023: 169 · 2022: 153 · 2021: 150 · 2020: 120 · 2019: 85 · 2018: 84 · 2017: 53 · 2016: 63 · 2015: 62 · 2014: 43 · 2013: 35 · 2012: 29
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- doxorubicin, anthracyclines, cardiotoxicity, drug toxicity mechanisms, anticancer mechanism, neurotoxicity, nephrotoxicity, hepatotoxicity, chemotherapy side effects
- MeSH terms
- Antibiotics, Antineoplastic, Doxorubicin, Humans, Molecular Conformation, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
